Physician profile
Morayma Martinez
NPI 1962475384
$8,522.45
in general payments reported to CMS, 2019-2025
37 companies · $49.86 in 2025
The $49.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,276 · 2021: $2,240 · 2022: $1,895 · 2023: $1,463 · 2024: $95.25 · 2025: $49.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $998.21 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $836.90 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $710.14 | 2019-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $700.56 | 2019-2023 | Xifaxan |
| Abbvie INC. | $513.49 | 2020-2024 | |
| Lilly USA, LLC | $472.58 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $455.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $410.35 | 2019-2023 | Xarelto |
| Pfizer INC. | $355.33 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $291.31 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $270.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $258.91 | 2019-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.45 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $237.98 | 2020-2023 | Leqvio |
| Eisai INC. | $215.56 | 2020-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morayma Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.